myrcludex-B

01/01/2022 - "The entry inhibitor myrcludex-B was used during the rebound phase to avoid new infection events. "
01/01/2019 - "Co-treatment with the entry inhibitor Myrcludex B ensured long-term control of HBV infection. "
01/01/2019 - "Despite 15 in vitro cell passages and block of viral spreading by Myrcludex-B, clonal cell expansion permitted amplification of HDV infection. "
11/21/2018 - "Here, we found that NTCP expression upregulated HBV transcription at the postentry step and that the NTCP-targeting entry inhibitor Myrcludex B (MyrB) effectively suppressed HBV transcription both in an HBV in vitro infection system and in mice hydrodynamically injected with an HBV expression plasmid. "
01/01/2016 - "Twenty-four patients with CHD infection were equally randomized (1:1:1) to receive myrcludex B, or PegIFNα-2a or their combination. "

01/01/2020 - "Myrcludex B treatment increased fecal energy output, explaining body weight reductions amongst unaltered food intake and energy expenditure. "
01/01/2020 - "Inhibition of NTCP by Myrcludex B in obese Oatp1a/1b KO mice inhibited hepatic clearance of bile acids from portal and systemic blood, stimulated GLP-1 secretion, reduced body weight, and decreased (hepatic) adiposity. "

06/20/2020 - "Conclusion: It is feasible to infect HepaRG cells with HBV positive serum supplemented with PEG in vitro, and the cell entry inhibitor myrcludex-B has a certain inhibitory effect on hepatitis B virus infection in this experimental model. "
06/01/2016 - "A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B."
01/01/2016 - "These results will allow testing myrcludex B in hepatitis B and D patients."
01/01/2016 - "Myrcludex B is a first-in-class compound, which blocks entry of hepatitis B and D virus into hepatocytes in vitro and in animal models. "
01/01/2016 - "First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B."

09/01/2015 - "As a proof of concept, the assay was applied to plasma samples derived from a clinical phase I study of myrcludex B, a novel first-in-class virus entry inhibitor for the treatment of chronic hepatitis B and D. "
01/01/2018 - "Myrcludex B is a first-in-class virus entry inhibitor for patients with chronic hepatitis B or B/D infections. "
01/01/2016 - "After 24weeks of treatment with myrcludex B and/or pegylated interferon α-2a, HDV R NA, a relevant marker for hepatitis D infection, decreased in all patients with chronic hepatitis B and D. "

01/01/2016 - "Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study."
01/01/2016 - "Myrcludex B, a novel therapy for chronic hepatitis D?"